181 result(s) found
Want Better Returns? Don?t Ignore These 2 Finance Stocks Set to Beat Earnings
https://www.zacks.com/stock/news/2203078/want-better-returns-don-t-ignore-these-2-finance-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2203078
Dec 28, 2023 - Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
0
TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value
https://seekingalpha.com/article/4660017-tscan-two-2024-tcr-t-data-readouts-could-bring-significant-value?source=feed_all_articles
Dec 27, 2023 - TScan's results from T-Plex targeting patients with solid tumors in the Phase 1 study are expected to be released in 2024. Read my analysis of TCRX stock.
0
Want Better Returns? Don?t Ignore These 2 Computer and Technology Stocks Set to Beat Earnings
https://www.zacks.com/stock/news/2202526/want-better-returns-don-t-ignore-these-2-computer-and-technology-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2202526
Dec 27, 2023 - Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
0
TCAF: A Promising Active Fund
https://seekingalpha.com/article/4659892-tcaf-promising-active-fund?source=feed_tag_etf_portfolio_strategy
Dec 27, 2023 - T. Rowe Price Capital Appreciation Equity ETF (TCAF) has seen significant growth, amassing over $600M in AUM in less than 6 months. Read more here.
0
Oncternal slips after early data for lymphoma therapy
https://seekingalpha.com/news/4050320-oncternal-stock-slips-lymphoma-drug-data?source=feed_sector_healthcare
Dec 26, 2023 - Oncternal Therapeutics (ONCT) shares fell in reaction to initial results from its Phase 1/2 study for CAR T cell therapy in B-cell lymphoma. Read more here.
0
Is Janus Henderson Triton T (JATTX) a Strong Mutual Fund Pick Right Now?
https://www.zacks.com/stock/news/2202039/is-janus-henderson-triton-t-jattx-a-strong-mutual-fund-pick-right-now?cid=CS-ZC-FT-mutual_fund_equity_report-2202039
Dec 26, 2023 - Mutual Fund Report for JATTX
0
AT&T Stock Is a Buy for This Reason
https://www.fool.com/investing/2023/12/24/att-stock-is-a-buy-for-this-reason/?source=iedfolrf0000001
Dec 24, 2023 - Investors have good reason to pay more attention to one particular metric.
0
Is T. Rowe Price Institutional Small-Cap Stock (TRSSX) a Strong Mutual Fund Pick Right Now?
https://www.zacks.com/stock/news/2200903/is-t-rowe-price-institutional-small-cap-stock-trssx-a-strong-mutual-fund-pick-right-now?cid=CS-ZC-FT-mutual_fund_equity_report-2200903
Dec 21, 2023 - Mutual Fund Report for TRSSX
0
T-Mobile: The New Telecom Leader
https://seekingalpha.com/article/4658950-t-mobile-the-new-telecom-leader?source=feed_all_articles
Dec 20, 2023 - T-Mobile's Q3 results show industry-leading metrics, impressive net additions, and strong financial performance. Read why TMUS stock is positioned for future growth.
0
T. Rowe Price (TROW) Crossed Above the 200-Day Moving Average: What That Means for Investors
https://www.zacks.com/stock/news/2200524/t-rowe-price-trow-crossed-above-the-200-day-moving-average-what-that-means-for-investors?cid=CS-ZC-FT-tale_of_the_tape|200_day_moving_average_(yseop)-2200524
Dec 20, 2023 - Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
0